Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Steven I Aronin"'
Publikováno v:
International Journal of Infectious Diseases, Vol 119, Iss , Pp 142-145 (2022)
[Abstract]: Antimicrobial resistance (AMR) can complicate effective management of urinary tract infections. We conducted a retrospective study of AMR in Enterobacterales urine isolates from ambulatory and hospitalized adult patients from 2018-2020 (B
Externí odkaz:
https://doaj.org/article/8f5156fb92ef4f2884574678552b298d
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Urinary tract infections (UTIs), which are usually caused by bacteria in the Enterobacterales family, are a common reason for outpatient visits. Appropriate empiric therapy for UTIs requires an understanding of antibiotic resistan
Externí odkaz:
https://doaj.org/article/bbad54ff117a43b28da0e0764ff129e7
Autor:
Michael W. Dunne, Sailaja Puttagunta, Steven I. Aronin, Stephen Brossette, John Murray, Vikas Gupta
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 1 (2022)
ABSTRACT Resistance to oral antibiotics commonly used to treat outpatient urinary tract infections (UTIs) is increasing, but the implications of empirical treatment of resistant pathogens are not well described. Using an electronic records database,
Externí odkaz:
https://doaj.org/article/058fb89eb63a498e8f1d43181a0a80fb
Autor:
Joshua M Maher, Michael D Huband, Christopher G Blankers, Sailaja Puttagunta, Steven I Aronin, Mariana Castanheira
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:1406-1414
Objectives Physicians must leverage several factors when making antibiotic therapy decisions, including route of administration and duration of therapy. Oral administration provides several potential advantages including increased accessibility, prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32557c75883eea7e7cdcfd1d7813a1ae
https://doi.org/10.1093/jac/dkad099
https://doi.org/10.1093/jac/dkad099
Autor:
Michael W Dunne, Steven I Aronin, Anita F Das, Karthik Akinapelli, Jeanne Breen, Michael T Zelasky, Sailaja Puttagunta
Publikováno v:
Clinical Infectious Diseases. 76:78-88
Background Sulopenem is a thiopenem antibiotic being developed for the treatment of multidrug-resistant infections. The availability of both intravenous (IV) and oral formulations will facilitate earlier hospital discharge. Methods Hospitalized adult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::325b8d15c9c6d2f5f4d53b4b2f8c84d4
https://doi.org/10.1093/cid/ciac704
https://doi.org/10.1093/cid/ciac704
Autor:
Michael W Dunne, Steven I Aronin, Anita F Das, Jayanti Gupta, Karthik Akinapelli, Michael T Zelasky, Sailaja Puttagunta, Helen W Boucher
Publikováno v:
Clinical Infectious Diseases.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6eeea49969a49d3e38bdca55c9f76853
https://doi.org/10.1093/cid/ciad166
https://doi.org/10.1093/cid/ciad166
Autor:
Sailaja Puttagunta, Steven I Aronin, Michael Dunne, Stephanie A Halasohoris, Ashley Babyak, Mary K Hourihan, James M Meinig
Publikováno v:
Open Forum Infectious Diseases. 9
Background Sulopenem is a thiopenem β-lactam antibiotic being developed for the treatment of infections caused by multi-drug resistant bacteria. Sulopenem is available as intravenous and oral pro-drug formulations, and its activity aligns with the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0e0b12cd9e562ed604e57aaf2efa93a
https://doi.org/10.1093/ofid/ofac492.1354
https://doi.org/10.1093/ofid/ofac492.1354
Publikováno v:
Open Forum Infectious Diseases. 9
Background Per FDA Guidance, the primary efficacy endpoint for trials evaluating antimicrobials for treatment of uncomplicated urinary tract infection (uUTI) and complicated urinary tract infection (cUTI) is a combined clinical/microbiologic outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9616d70f8a276fe8e885db52ce015a1d
https://doi.org/10.1093/ofid/ofac492.305
https://doi.org/10.1093/ofid/ofac492.305
Autor:
Michael W Dunne, Steven I Aronin, Anita F Das, Karthik Akinapelli, Michael T Zelasky, Sailaja Puttagunta, Helen W Boucher
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Background There are limited treatment options for uncomplicated urinary tract infection (uUTI) caused by resistant pathogens. Sulopenem etzadroxil/probenecid (sulopenem) is an oral thiopenem antibiotic active against multidrug-resistant pathogens th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393d7314055537aa4009f345fb5135b9
https://pubmed.ncbi.nlm.nih.gov/36069202
https://pubmed.ncbi.nlm.nih.gov/36069202
Publikováno v:
Diagnostic microbiology and infectious disease. 103(4)
Antimicrobial resistance in Enterobacterales has made empiric therapy for hospitalized patients with urinary tract infections (UTIs) more challenging. We analyzed the antibiotic susceptibility of nonduplicate Enterobacterales isolates from urine cult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dea3f46d206a1520df8240423c5be8f
https://pubmed.ncbi.nlm.nih.gov/35635889
https://pubmed.ncbi.nlm.nih.gov/35635889